Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026

(NASDAQ:IMMX) Immix Biopharma, Inc. announced it will present an abstract on NXC-201 at the American Society of Hematology (ASH) 68th Annual Meeting and Exposition, scheduled for December 12-15, 2026, in New Orleans, LA. The oral presentation, titled “45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis,” will be delivered during the session “652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis” on Monday, December 14, 2026, from 10:30 AM to 12:00 PM Central Time, with the presentation itself at 11:15 AM. The abstract publication number is 826. AL amyloidosis is described as a disease where the immune system produces toxic light chains that accumulate in organs, leading to organ failure and death, and is the most common form of amyloidosis according to the National Institutes of Health. The number of U.S. patients with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year, reaching approximately 30,506 patients in 2026, based on Staron et al in Blood Cancer Journal. The amyloidosis market was valued at $6.2 billion in 2025 and is expected to reach $6.6 billion in 2026, according to Grand View Research. Immix Biopharma’s lead candidate is NXC-201, a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge, and binder “digital filter” designed to filter out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study NEXICART-2 (NCT06097832) for relapsed/refractory AL Amyloidosis, with a potentially registrational design. NXC-201 has received Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) from the US FDA, as well as Orphan Drug Designation (ODD) from both the FDA and the EMA.